The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
By subject
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
One price in Japan, response-linked payments in Australia, no public price in China: CAR-T sponsors face three markets.
CMS Set December 2027 for Insurers’ Prescription Drug Price Files, a Requirement on Hold Since 2021
The drug file reaches manufacturers, and the schema due around May 2027 decides how much net price becomes public.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark turned a January no on Tecartus into a yes by tying price to response, and renewed burosumab on a lower price.
Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS
Exclusion only works as leverage when the excluded drug has no market. Mounjaro has one, and Lilly built the channel.
ICER Says AstraZeneca’s $10,950 Baxfendy Is Worth $1,400 to $2,500 a Year
ICER has handed payers the case for putting Baxfendy behind generics, and Mineralys gets its price anchor before launch.
Shionogi Paid 29 Times Sales for IntraBio, 17 Days After AQNEURSA’s Second FDA Approval
Shionogi paid about 29 times sales for a drug that gained its second indication 17 days before the deal was signed.
CSL Paid $355 Million and Gave Up 45% of the Profits to Win a Claudin-1 Antibody
No development milestones and no royalty: CSL funds every trial through Phase 3 and gives Alentis 45% of the profits.
France Trades €100 Million in Price Relief for an Annual Review of Older Drugs
France has moved the reimbursement threat from price to presence: a competitor’s launch can now put an incumbent under review.